SimBioSys Secures FDA Clearance for TumorSight® Risk, Introducing the World's First AI-Powered, MRI-Derived Breast Cancer Recurrence Risk Assessment
Novel software transforms routinely collected MRI, pathology and clinical data into personalized five- and ten-year recurrence risk insight for women with early-stage breast cancer CHICAGO, Oct. 15, 2026 /PRNewswire/ -- SimBioSys®, an AI-driven precision medicine company revolutionizing...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.